To get a comprehensive picture across hematological tumors, we assessed IGF2BP3 mRNA levels in 6832 hematological cancers that included 24 different disease entities [24,25]. This evidence concerns the gene IGF2BP3 and hematopoietic and lymphoid cell neoplasm.